The concept of 'systemic metastatic dissemination of cancer cells from the early phases of their oncogenesis', which is referred to here as 'cancer early dissemination' for short, was established by pioneer works of C. A. Klein and colleagues. In their cohort studies of breast cancer patients, they provided the first evidence that breast cancer cells can disseminate into the bone marrow in a far less progressed genetic state than previously thought, and hence discussed that genomic aberrations that make them metastatic (i.e., outgrowing from the sites of dissemination) might be acquired after this step (1) . This notion was confirmed experimentally using mouse models for human breast cancer (2) . Metastasis is the greatest threat of cancer. According to the model of 'cancer early dissemination', it is easy to understand the very late appearance of metastatic lesions, long after the resection of a primary tumor as well as its regional lymph nodes, as C. A. Klein has mentioned. Early disseminated tumor cells will acquire genome alterations independent of the primary site after leaving, that allow them to grow out. Thus, this model may also imply that therapies based on characters of the primary tumors have some limitations when treating metastatic lesions and recurrent cancers, that have originated from early disseminated cells. This model also shed a new light on 'cancer of unknown primary (CUP)', which comprises up to 7% of cancer patients bearing metastases, whose primary tumor remains unrecognized.
Mechanisms of cancer early dissemination are still largely unidentified.
From a cell biological point of view, however, early dissemination is a phenomenon rather easy to understand because full-transformation is not necessary to move out ( Fig.   1 ). Obviously, because of the lack of the full transformation, early disseminated cells do not outgrow immediately at their sites of dissemination, but instead sometimes become dormant, as has been demonstrated using untransformed mammary epithelial cells (3) . Cancer is a tissue-specific disease, and studies discussed in this review are mostly carried out with breast cancers, while some parts of the intracellular mechanisms and signaling have yet to be confirmed in this cancer.
Cancerous EMT
EMT is a normal cellular process of epithelial cells in which their E-cadherin is downregulated and certain integrins are upregulated in order to move out of the epithelial cell layer, described originally by E. Hay (4) . EMT occurring in normal cells involves many changes including an alteration in the expression of intermediate filaments, from cytokeratins to vimentin. However, cancer cells often express both cytokeratins and vimentin simultaneously (5) , indicating that the EMT-like process which occurred in most cancer cells is not normal. Here I will refer to the EMT-like processes of cancer cells as 'cancerous EMT'.
Loss of E-cadherin: not simply the disruption of cell-cell adhesions resulting in cells to move-out
A long-standing question is whether the loss of E-cadherin-mediated cell-cell adhesion is enough to render cells to move-out. On the other hand, it is well known that E-cadherin associates with -catenin, which is bifunctional and acts as a transcriptional co-activator, such as of Tcf/Lef in the nucleus. The current prevailing model suggests that association of E-cadherin with -catenin suppresses -catenin from entering into the nucleus to prevent transformation. A question is whether this is true.
Onder et al. (6) have addressed this issue by the use of HMLER cells, which are generated by immortalization of human primary normal mammary epithelial cells by introducing hTERT and SV40 large T antigen, followed by the introduction of H-Ras to make them tumorigenic (7) . Although HMLER cells are highly tumorigenic, they are not metastatic on their own. Onder et al. have shown that the disruption of cell-cell adhesions by a dominant-negative form of E-cadherin is unable to facilitate their metastasis (6) . On the other hand, loss of E-cadherin expression by shRNA renders HMLER cells to be invasive, anoikis resistant, and highly metastatic. Similar results has been shown by others (8) . Gene expression profiles indicated that HMLER cells undergo EMT upon loss of E-cadherin expression. However, Onder et al. also show that the nuclear accumulation of -catenin is not sufficient, although necessary, to induce the metastatic properties. Therefore, the loss of E-cadherin expression, but not simply the loss of E-cadherin-mediated cell-cell adhesions, appears to be a key for cancer cells to move out. Twist was originally found as an inducer of mesoderm formation in Drosophila (9); and is expressed upon the onset of EMT to suppress gene transcription including the CDH1 (E-cadherin) gene in mammals (10) . Twist is induced upon the loss of E-cadherin expression in HMLER cells (6) . Twist may well contribute to cancer malignancy, perhaps even independently of the suppression of E-cadherin expression (also see later).
TGF1 signaling is the most frequent factor inducing mesenchymal and stem-like properties of breast cancer cells TGF is one of the EMT-inducing factors. Under physiological conditions, TGF exhibits biphasic roles in both the promotion and inhibition of branching morphogenesis of mammary gland ducts, depending on their concentration and cellular context (11) .
In cancer, TGF signaling also appears to be biphasic: it acts as a tumor suppressor during early oncogenesis, while in later stages it is often a tumor promoter (12, 13) .
Among the different signaling pathways, TGF signaling appears to be most frequently involved in inducing the mesenchymal and cancer stem cell-like property of primary human breast cancers. The gene expression profile of CD44+/CD24-/low breast cancer cells resembles that of stem cells (14) . Moreover, CD44+ breast cancer cells are negative for estrogen receptor (ER) even in some ER+ cancers and are refractory to current adjuvant hormonal therapy (15) . In these cancers, ER is From these data, oncogenic Ras signaling and abrogating the normal function of p53 and /or Rb seem to be involved in processes that make mammary epithelial cells able to undergo EMT and become cancer stem cell-like, in response to TGF or Twist.
Balancing proliferative and cytostatic programs: roles of wild type p53
p53 functions both in the nucleus and the cytoplasm, and its mutation is very common in cancer (18) . Upon accumulation in the nucleus, wild type p53 participates in transcriptional regulation of a number of genes via specific DNA elements, in which each set of expressed gene products is thought to be engaged either in the control of cell cycle arrest, differentiation, senescence or apoptosis. Wild type p53 thereby exhibits cytostatic and tumor suppressive properties. Wild type p53 also appears to be important in the regulation of polarity of cell division in mammary stem cells, and its loss is coupled with the symmetric division of cancer stem cells and may hence contribute to tumor growth (19) . clinically with relation to a significant high probability to develop recurrence of breast cancers (38) . Of note, Sharp-1 and Cyclin G2 are not contained in the previously known gene signature for breast cancer metastasis (38) .
Molecular machineries required for cancerous EMT
Sharp-1 and Cyclin G2, as well as p53 and Smads, are all basically engaged in the regulation of gene expression, while they each regulate groups of genes rather than a certain single gene. Moreover, their target genes are not fixed intrinsically, but are altered depending on cellular contexts and other transcriptional factors they may work with. Therefore, while understanding the status of such factors that regulate gene expression and genome status is very important, attempting their understanding may sometimes be frustrating, like seeing shadow pictures. Another aspect towards the substantial understanding would be to understand the molecular machineries that actually accomplish the properties of cancer malignancy. Below I briefly discuss the molecular machineries that execute cancerous EMT and the moving out.
Core events for EMT are the activation of integrin and the inactivation of E-cadherin. Integrins are activated in two ways. One is the conformational change, which has already been discussed extensively in other reviews (39) . Another aspect is their de novo synthesis and the recycling. It is well known, for example, that transcription of the 1integrin gene is induced during TGF1-induced EMT of mammary epithelial cells (40) , although the transcriptional control is not discussed here.
On the other hand, integrin actively recycles between the plasma membrane and early endosomes, recycling which has been demonstrated to constitute a basic machinery driving cell migration (41) . Moreover, functions of integrin in cancer cells include phagocytosis of degraded ECM components, which also involves endocytosis.
Arf6 is primarily involved in the recycling of plasma membrane components (42) , and its signaling greatly contributes to invasive and metastatic activities of many breast cancer cells (43) (44) (45) (46) . Arf6 colocalizes with β1 integrin at endosomes and is implicated in serum-induced recycling-back of β1 integrin (47, 48) . β1integrin forms a complex with several Arf GTPase-related proteins, to be under the control of Arf6. It has been shown that ACAP1, a GTPase activating protein for Arf6, forms a complex with β1 integrin, and this complex formation is regulated by Akt to be dependent on external stimulations (49) . In breast cancer, β1 integrin associates with AMAP1 Rab GTPases are also important. The above mentioned PRKD1-mediated recycling-back of β3 integrin appears to be dependent on Rab4, but not Rab11 (53, 54) .
On the other hand, Rab11, but not Rab4, has been shown to be involved in the endosomal colocalization of β1 integrin with Arf6, and its recycling (48) . Moreover, Rab11 is involved in the trafficking of β4 integrin in hypoxia-induced invasion of some breast cancer cells (56) . Rab GTPases consist of more than 80 isoforms in humans, while Arf6 is the sole member among the Arf-family GTPases to be involved in (57) . The results of siRNA-mediated knockdown of GEP100 and of Arf6-/-mice also support this notion (58, 59) . Moreover, activation of Arf6 by GEP100 disrupts E-cadherin adhesion, while activation of Arf6 by other GEFs does not (45) .
We have moreover shown that Git1 is responsible for the inactivation of Arf6 at the plasma membrane in order to prevent E-cadherin from being endocytosed (60) . In this mechanism, Git1 was found to be activated by EphA2, whose dysfunction is frequently observed in malignant cancers. We have moreover shown that EPB41L5 is induced during EMT and is essential for EMT conversion, by facilitating E-cadherin endocytosis (61) . 
